Rocket Pharmaceuticals, Cranbury, NJ

Rocket Pharmaceuticals

www.rocketpharma.com

Rocket Pharma (NASDAQ: RCKT) is a fully-integrated, clinical-stage company advancing numerous gene therapies that could cure rare childhood diseases. Rocket places enormous value on people and takes team member progress and well-being just as seriously as the progress and well-being of its pipeline. We are looking for hands-on team players that enjoy collaborating with colleagues who share a passion for seeking gene therapy cures for devastating diseases and making a difference for patients. Become an integral part of a small, highly productive team and help grow an entrepreneurial, scientifically driven organization that is increasingly recognized as a leading biotechnology innovator. ...

More>>

Number of Employees: 100-250
Annual Revenue: $10-50 Million

www.rocketpharma.com
9 Cedarbrook Drive
Cranbury, NJ USA 08512
Phone: 646.440.9100

Name	Title	Contact Details
Kinnari Patel	President, Head of Research & Development and Chief Operating Officer	Profile
Chris Stevens	Chief Operating Officer	Profile
Chantal Petit	VP, Chief of Staff supporting the President/Head R&D/COO at Rocket Pharmaceuticals	Profile
Mayo Pujols	Executive Vice President and Chief Technical Officer	Profile

Similar Companies

Front Range Biosciences

Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.

Cue Biopharma

Cue Biopharma™ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient`s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform™. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

CTOs on the Move